A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HS (clinicaltrials.gov) - Oct 3, 2026 - P1 | N=30 | Not yet recruiting | Sponsor: Novartis Pharmaceuticals
New P1 trial • Dermatology • Hidradenitis Suppurativa • Immunology
|